A team of researchers say a two-hormone approach to type 2 diabetes appears to reduce sugar levels as well as chip away at obesity. The experimental two-in-one combination fuses a GLP-1 and a gastric inhibitory peptide. Digestive processes naturally trigger these two hormones. Researchers say their simulation maximizes the metabolic impact of these hormones which also influence appetite and fat burning. The study incorporated data from Roche and was published in Science Translational Medicine.